In any case, the interconnection among the effects of Aβ, BDNF and the plasminogen activation system suggests that, independently from its origin, this mechanism might be responsible for many clinical features of AD and that a pharmacological treatment targeting elements of this circuit, such as for example PAI‐1, is likely to produce a cascade effect. The gene discussed is BDNF; the disease is Alzheimer disease.